首页> 外文期刊>General Pharmacology >Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits.
【24h】

Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits.

机译:阿托伐他汀对血脂异常兔的内皮依赖性收缩因子的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Relaxations to acetylcholine and contractions to acetylcholine in the presence of the nitric oxide (NO) synthesis inhibitor (L-N(G)-nitroarginine methyl ester, L-NAME) were studied in aortic rings from rabbits fed either a control or a diet containing 0.5% cholesterol+14% coconut oil for 14 weeks and treated or not with atorvastatin (2.5 mg kg(-1) day(-1)). Rings were incubated with the endothelin (ET(A)) receptor antagonist BQ123, and/or the thromboxane A(2) (TXA(2))/prostaglandin H(2) (PGH(2)) receptor antagonist ifetroban. In rabbits, high cholesterol and triglyceride plasma levels were associated with intimal thickening and blunted acetylcholine-relaxation as compared with controls. By contrast, acetylcholine+L-NAME response was higher. Incubation with either ifetroban or BQ123 increased acetylcholine-relaxation in both diet groups and it reduced the constrictor response only in dyslipidemic rabbits. Removal of endothelium reduced acetylcholine+L-NAME contraction in dyslipidemic rabbits, although increased it in control animals. Atorvastatin treatment reduced plasma lipid levels and lesion size in dyslipidemic animals. Likewise, it prevented acetylcholine-relaxation reduction. In addition, atorvastatin reduced constrictor response in dyslipidemic rabbits but only in rings with endothelium. Incubation with either ifetroban or BQ123 did not further modify these responses in atorvastatin-treated animals in any group. These data suggest that ET and TXA(2) availabilities seem to participate in the endothelial dysfunction associated with dyslipidemia. Atorvastatin treatment reduces intimal thickening and improves endothelial dysfunction in rabbits. This effect seems to be a consequence of its ability to act on ET and TXA(2) systems.
机译:研究了一氧化氮(NO)合成抑制剂(LN(G)-硝基精氨酸甲酯,L-NAME)存在下对乙酰胆碱的松弛和对乙酰胆碱的收缩,研究对象是饲喂含对照或0.5%日粮的兔子的主动脉环胆固醇+ 14%椰子油治疗14周,是否接受阿托伐他汀治疗(2.5 mg kg(-1)天(-1))。环与内皮素(ET(A))受体拮抗剂BQ123和/或血栓烷A(2)(TXA(2))/前列腺素H(2)(PGH(2))受体拮抗剂ifetroban一起孵育。与对照组相比,家兔体内的高胆固醇和甘油三酸酯血浆水平与内膜增厚和乙酰胆碱松弛钝化有关。相反,乙酰胆碱+ L-NAME应答较高。与非特罗班或BQ123一起温育在两个饮食组中均增加了乙酰胆碱的松弛,仅在血脂异常的兔子中降低了收缩反应。去除内皮减少了血脂异常兔子的乙酰胆碱+ L-NAME收缩,尽管在对照动物中增加了。阿托伐他汀治疗降低了血脂异常动物的血脂水平和病变大小。同样,它防止了乙酰胆碱松弛的减少。此外,阿托伐他汀可减少血脂异常兔子的收缩反应,但仅在具有内皮的环中。在任何一组中,用非特罗班或BQ123孵育均未进一步改变受阿托伐他汀治疗的动物的这些反应。这些数据表明,ET和TXA(2)的可用性似乎参与了与血脂异常有关的内皮功能障碍。阿托伐他汀的治疗减少了兔子的内膜增厚并改善了内皮功能障碍。此效果似乎是由于其对ET和TXA(2)系统起作用的能力的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号